Less Doses of Daratumumab Are Adequate to Achieve Response in Newly Diagnosed Multiple Myeloma

The goal of this clinical trial is to evaluate whether a modified (less frequent) dosing schedule of daratumumab, when added to standard VRd therapy, can be an effective induction regimen for treating newly diagnosed multiple myeloma (NDMM). The main questions it aims to answer are: 1. Does the modified (less frequent) daratumumab dosing regimen increase the rate of MRD (minimal residual disease) negativity after 4 cycles of induction therapy (as compared to standard VRd therapy)? 2. Is the modified less-frequent dosing schedule safe and does it achieve adequate drug levels 3. What is the cl

Trial Details

NCT ID
NCT07891923
Phase
PHASE2
Sponsor
Tata Memorial Centre
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Daratumumab (Intravenously)
  • Bortezomib (BTZ)
  • Len (lenalidomide)
  • Dexamethasone
Locations (sample)
  • Navi Mumbai, Maharashtra, India|19.03681,73.01582
  • Navi Mumbai, Maharashtra, India|19.03681,73.01582

Key Eligibility Criteria

  • Newly diagnosed multiple myeloma
  • ECOG performance status 0-2
  • Age ≥18 years of age
  • Acceptable liver functions, as specified below: Total bilirubin \<2 times upper limit of normal (ULN), Aspartate transaminase (AST; SGOT), alanine …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →